Targeting Chorea in Huntington’s Disease: Emerging Therapeutic Strategies
Bibliographic record
Abstract
Huntington's disease (HD) is a currently incurable neurodegenerative disorder caused by an autosomal dominant mutation in the HTT gene, leading to the production of mutant huntingtin protein (mHTT) with an expanded polyglutamine (polyQ) tract. This aberrant protein aggregation results in progressive neuronal dysfunction, particularly in the striatum and cortex, manifesting as involuntary choreiform movements (resembling dance-like behaviors), cognitive decline, and psychiatric disturbances. Despite advances in symptomatic management—such as antidepressants, dopamine-modulating agents, and physical therapy—existing treatments fail to halt disease progression or reverse neuronal damage.In recent years, novel therapeutic strategies have emerged, offering hope for disease modification rather than mere symptom alleviation. One promising approach involves mini-intrabodies, engineered antibody fragments designed to selectively bind and neutralize mHTT. These intrabodies facilitate the degradation of toxic protein aggregates via lysosomal pathways, effectively reducing neuronal toxicity. Other cutting-edge interventions include antisense oligonucleotides (ASOs) to suppress mHTT expression, CRISPR-based gene editing to correct the HTT mutation, and stem cell therapy to replace damaged neurons.This article evaluates these innovative strategies, with a focus on lysosome-targeted mini-intrabodies as a potential curative approach. By analyzing preclinical and clinical advancements, we aim to highlight future research directions that could transform HD treatment from palliative care to definitive therapy.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".